Thymalin vs VIP.

Thymalin is a peptide preparation originally isolated as a polypeptide fraction from calf thymus gland, developed by Vladimir Khavinson's group in the Soviet Union and Russia. It belongs to the family of so-called peptide bioregulators and is associated with short peptide sequences (notably Lys-Glu and Glu-Trp) proposed as its active elements. It is positioned as a thymic immunomodulator intended to counter age-related decline of the thymus and T-cell immunity. In Russia it is a registered pharmaceutical; elsewhere it is treated as a research compound.

VIP (vasoactive intestinal peptide, also called vasoactive intestinal polypeptide) is a 28-amino-acid neuropeptide first isolated from porcine intestine in the early 1970s. It is highly conserved across mammals and belongs to the secretin/glucagon peptide superfamily, sharing close homology with PACAP (pituitary adenylate cyclase-activating polypeptide). It is widely distributed in the central and peripheral nervous systems and in the gut, and is notably enriched in lung tissue. The synthetic form used in human trials is known as aviptadil.

Thymalin is proposed to act as an immune bioregulator that supports differentiation and function of T-lymphocytes and helps normalize the T-helper/T-suppressor balance. The Khavinson group hypothesizes that its constituent short peptides can enter cells and interact with DNA and chromatin to modulate tissue-specific gene expression, nudging an aged or dysregulated immune system toward a more youthful pattern. Some experimental work reports effects on the differentiation of hematopoietic stem cells. These proposed mechanisms are largely derived from the originating laboratory's own animal and cell studies rather than from independent mechanistic confirmation.

VIP signals through two class B G-protein-coupled receptors, VPAC1 and VPAC2, both of which bind VIP and PACAP with high affinity (a related receptor, PAC1, is PACAP-selective). Receptor activation couples primarily to adenylate cyclase, raising intracellular cAMP, with secondary coupling to phospholipase C in some contexts. Downstream effects include smooth-muscle relaxation and vasodilation, bronchodilation, stimulation of exocrine and electrolyte secretion, glucose-dependent insulin secretion (largely via VPAC2), and broad immunomodulatory/anti-inflammatory actions that shift cytokine balance away from pro-inflammatory mediators. In the lung, VIP receptors are concentrated on alveolar type II cells, which is part of the rationale for studying it in acute lung injury.

The published evidence for thymalin comes overwhelmingly from Vladimir Khavinson and collaborators, appearing mainly in Russian-language journals and outlets such as Bulletin of Experimental Biology and Medicine and Neuro Endocrinology Letters. The most cited human data is a multi-year, non-blinded geroprotection program in elderly subjects reporting improved immune parameters and lower mortality versus controls, but it was not a modern blinded, independently replicated randomized controlled trial. That program was reported retrospectively across several summary papers rather than as a single prespecified protocol, and the published accounts do not describe randomization procedure, allocation concealment, blinded outcome assessment, prespecified primary endpoints, or independent data monitoring. Companion reviews such as the 2002 Neuro Endocrinology Letters paper on peptides and ageing present thymalin alongside epithalamin as part of a single geroprotective program, so the human results for the two preparations are frequently reported together rather than separately. More recent papers describe effects on hematopoietic stem cell differentiation and gene expression, again largely from the same group and largely in cell culture, including work on peptide regulation of immune and inflammatory pathways in spleen tissue and in monocyte and macrophage cell lines. Independent Western replication in rigorous RCTs is essentially absent, so the evidence base should be read as preliminary and heavily single-source. Readers should weigh the near-total reliance on one research group when interpreting any claims. The contrast with Cerebrolysin is a useful calibration: Cerebrolysin, another animal-tissue peptide preparation, has accumulated enough independent randomized trials to support two Cochrane systematic reviews, and those reviews still reached cautious and largely non-endorsing conclusions. Thymalin has not reached even that level of external scrutiny, and it shares this position with the other bioregulators in the same tradition, notably vilon, cortexin and epitalon. What is not known is substantial: there is no published modern toxicology package, no pharmacokinetic characterization of the fraction in humans, no batch-to-batch potency standard visible in the international literature, and no registration-quality trial outside Russia.

Human evidence is mixed and, for most systemic indications, limited. The strongest, most rigorous human data come from TESICO (ACTIV-3b), a randomized, placebo-controlled trial of intravenous aviptadil in COVID-19-associated hypoxaemic respiratory failure published in Lancet Respiratory Medicine (2023); it enrolled ~471 randomized participants and was stopped for futility, finding no improvement in clinical outcomes versus placebo. The earlier enthusiasm rested largely on small open-label series and preclinical/animal models of acute lung injury and cytokine suppression, which did not translate into proven benefit in the controlled setting. The best-established human use is local, not systemic: aviptadil combined with phentolamine (Invicorp) is an approved intracavernosal injection for erectile dysfunction in several countries. VIP has also held orphan-drug designations for pulmonary hypertension and sarcoidosis, but those indications lack confirmatory pivotal trial evidence.

Reported human and animal experience describes thymalin as generally well tolerated in the contexts studied, with few documented serious adverse effects in the originating literature. However, because independent long-term safety data and modern regulatory review outside Russia are lacking, its safety profile in broad populations is not well established, and the absence of reported harms in single-group publications is weak evidence of safety rather than positive evidence of it. As a parenteral preparation derived from calf tissue, it carries the generic concerns that apply to all animal-sourced injectable biologicals: hypersensitivity and anaphylactoid reactions to foreign protein, immunogenicity on repeated exposure, injection-site reactions, and dependence on the source herd and the purification process for freedom from adventitious agents. An agent proposed to modulate T-cell function also raises a theoretical question in autoimmune disease and in people taking immunosuppressive therapy, and that question has not been studied. Product purity and identity are also uncertain for material obtained outside regulated pharmaceutical channels, where lyophilized vials sold as research chemicals carry no verified sterility, endotoxin or content assay. A genuine safety evaluation would require what the existing literature does not provide: prospective adverse-event capture, immunological and hepatic and renal laboratory monitoring, anti-drug antibody testing, and follow-up long enough to detect delayed effects. This is educational information only and not medical or dosing advice.

As an endogenous vasodilator, systemic VIP/aviptadil can cause hypotension, flushing, and diarrhea, and intravenous infusion has been associated with these effects in trials. Excess endogenous VIP, as seen in VIPoma tumors, produces severe secretory (watery) diarrhea, hypokalemia, and dehydration, illustrating its potent secretory pharmacology. For intracavernosal use, the combination product is reported to carry low rates of penile pain and priapism relative to some other injectables. Long-term safety of systemic administration is not well characterized, and the controlled COVID-19 data did not establish a net clinical benefit; safety beyond the studied settings remains uncertain.

Thymalin is registered and used as an approved medicine in Russia, where it has a long clinical history. It is not approved by the US FDA or the European Medicines Agency and has no approved indication in the US, where it would be considered an unapproved research substance. It is not a dietary supplement.

VIP itself is not an FDA-approved drug; intravenous aviptadil is investigational in the United States and was studied under FDA mechanisms including orphan-drug designations (pulmonary hypertension, sarcoidosis) and emergency COVID-19 trials. The aviptadil/phentolamine combination (Invicorp) is approved for erectile dysfunction in several countries including the UK, Denmark, and New Zealand, but not broadly in the US.